HBOT Conversations:
Dr. Paul Harch & Viral / Bacterial Infections

Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.

He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.

This episode on a variety of viral & bacterial infections, combined with a few inflammatory conditions is the final episode in our nine episode series that has been released weekly with Dr. Harch.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

In this final episode of HBOT News Conversations with Dr. Harch, host Edward di Girolamo takes this time to review a handful of indications we have yet to discuss.

This episode will touch on using Hyperbaric Oxygen Therapy for viral illnesses of AIDS and long-haul COVID, the bacterial illness of Lyme Disease, and the Inflammatory conditions of Migraines, Chronic Fatigue Syndrome, Vaccine Injuries, and Asthma.

AIDS — HBOT does not have, that we know of, much direct antiviral effect. In general, it is not necessarily toxic to the virus. AIDS is an immunosuppressive disease and the virus is only part of the story; AIDS patients have a dysregulated immune system and there is damage that results from that. Dr. Harch specifically discusses a HBOT and AIDS report on some scuba divers; lobster fisherman in Puerto Rico who had AIDS, with the results showing improvement in their blood counts and overall health. There hasn’t been much follow-up on this or any study referencing AIDS and HBOT, but Dr. Harch would still encourage AIDS patients to try Hyperbaric Oxygen Therapy to improve their quality of life since HBOT has a direct positive response on an immune system’s inflammatory reaction.

ASTHMA — Asthma is an inflammatory condition of the lung.  Since HBOT upregulates the anti-inflammatory gene and downregulates the inflammatory gene, it definitely makes sense to treat Asthma with HBOT. Dr. Harch references the famous HBOT case of Mici Teller, Dr. Edward Teller’s wife. She was a tobacco addict, terrible smoker, and had destroyed her lungs.  She was on supplemental oxygen and had dementia from both the effects of the tobacco, cigarettes, and hypoxia. Dr. Teller had a stroke and Dr. Richard Neubauer sent a hyperbaric chamber out to him to treat him for his stroke. Mici was also placed in the HBOT chamber to treat her pulmonary disease. Not only did she get off oxygen (and she was dying at the time); it rejuvenator her. She lived another five years! Her dementia was ameliorated, and she had a fairly noticeable and dramatic improvement.  In this case, HBOT was purely treating the original lung disease, but they found it was also benefiting her brain, so they continued HBOT treatments. Dr. Teller became a vocal advocate for HBOT, and did over 3,000 dives until he died in his 90s.  He contributed his long life to Hyperbaric Oxygen Therapy and voiced that this is a treatment that requires more focus and study.

LYME DISEASE — Dr. Harch explains that he does not treat Lyme Disease patients with Hyperbaric Oxygen unless they’re receiving treatment for an active Lyme infection, or there’s certainty that the patient is no longer actively infected and now they have a residual neurological injury. Reason being, it’s too difficult to dose them properly. But HBOT does have potential to benefit a Lyme Disease patient, especially in conjunction with some anti-Lyme therapy for residual injury. Many Lyme patients have received HBOT and swear by the healing effects of it.

MIGRAINES — Migraines appear to occur when a reactivity enters a sensitivity of cerebral blood vessels and there is contraction and dilation in response to various stimuli; such as chemicals, hormones, trauma.  If you’re getting migraines from trauma, there are many reliable and fascinating studies available referencing the use of Hyperbaric Oxygen Therapy to gain migraine relief from post-concussive syndrome.  Dr. Harch also clarifies that reactive blood vessel migraine headaches and cluster headaches do also typically respond to HBOT, and about 93% of his patients have experienced headache relief almost instantly.  He references Bill Duncan, who had complete cessation of his headaches after two treatments (back in 2001) and to this day they have still not returned thanks to the power of Hyperbaric Oxygen Therapy.

CHRONIC FATIGUE SYNDROME — Dr. Harch believes that most Chronic Fatigue patients are experiencing brain-based symptoms.  While he has had great success in treating Chronic Fatigue Syndrome in his patients, he clarified that he does make a significant effort to identify the cause of CFS.  Chronic Fatigue can be secondary to carbon monoxide poisoning or other forms of toxicities — chemical toxicities or mold, for instance.  So, he stresses that yes, HBOT tends to work wonders for CFS but it’s just as important to identify the “why”, because then you can be a little more specific in the treatment protocol within the realm of that certain pathology.  In many cases, the “why” is never identified, but Dr. Harch again stresses to at least try to find out why the patient is suffering from CFS. Even if you can’t, Hyperbaric Oxygen Therapy has been very beneficial to relieving the debilitating symptoms of Chronic Fatigue Syndrome.

LONG-HAUL COVID — Dr. Harch discusses how a person’s reaction to the viral infection of COVID is different for everyone.  Overall, it is our individual immune system reaction that determines the severity of the disease. In some people their immune systems are dysfunctional and they can have a greater abnormal immune response that results in their death or severe problems in the long run. The biggest problem is the persistent inflammation post-COVID creates in Long-Haul COVID patients. It’s different with each person what part or organ system in their body has the dominant inflammation. However, one of HBOT’s dominant effects on disease pathophysiology is it’s affect on inflammation in a dysfunctional immune system. HBOT just makes sense to treat the lingering inflammation in Long-Haul COVID patients, and the response rate for bringing patients back to their baseline has been phenomenal. For some patients it only takes a few treatments, and for some it takes 40 – but overall, yes…. Hyperbaric Oxygen Therapy absolutely is showing great promise in treating Long-Haul COVID patients.

VACCINE INJURIES — Dr. Harch explains that viewers should take time to watch the FLCCC weekly webinar where he and other doctors in the hyperbaric world specifically discusses the use of Hyperbaric Oxygen Therapy to treat vaccine injuries. Vaccines stimulate the immune system, and the problem with some vaccines and especially with the COVID vaccines, is that the COVID vaccines stimulate an immune response and they never underwent long-term testing. The documented side effects of vaccines are underreported, but Dr. Harch did bring to our attention that the documented side effects through the government’s Vaccine Adverse Events Reporting System, VAERS, is greater for the COVID vaccine than the sum of all vaccine adversity events reported through that system in the past three or four decades! HBOT is a treatment for immune dysfunction and inflammation, so Dr. Harch urges anyone who has experienced a COVID vaccine injury, or any vaccine injury, to seek out Hyperbaric Oxygen Therapy.

Dr. Harch sums up his time at HBOT News Network by reminding everyone how Hyperbaric Oxygen Therapy started, in relationship to treating many ill patients at once. It was during the Spanish Flu pandemic, which is essentially a relative of the coronavirus pandemic, when Dr. Cunningham created a large hyperbaric chamber from spare parts of an old boiler. People started flocking to him for treatment because it was literally saving the lives of Spanish Flu victims who were on their last breath.  The pressure alone was enough to save the lives of many, but imagine if they had antibiotics then to treat the secondary pneumonia that came from the viral infection — so many more lives could have been saved.  Dr. Harch recommends Vance Trimble’s book, “The Uncertain Miracle” to learn more about the use of Hyperbaric Oxygen Therapy during that time period.  He stresses that today the medical industry isn’t reinventing the wheel with HBOT, they’ve just studied it longer, figured it out better, and witnessed the miraculous effects of healing with HBOT for a large variety of indications.

di Girolamo ends the segment asking Dr. Harch, “If God could give you one miracle related to Hyperbaric Oxygen that you could request and get. What would that miracle be?” Dr. Harch responds that he wishes for the mass distribution and access of Hyperbaric Oxygen Therapy. He wishes for the day that HBOT could be readily accessed and available to anyone with no barriers to receive it.

Please share Dr. Harch’s HBOT News Conversation segments. Maybe together we can all make that miracle a reality.

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Guest

Dr. Paul G. Harch

Dr. Paul G. Harch, MD

Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.

Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.

Harch HBOT – Hyperbaric Oxygen Therapy Clinic

5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/

Recent HBOT News

Clinical Trial – HBOT Late Radiation Tissue Injury

Background: Radiotherapy is a common treatment for many malignancies. Radiation-related
complications developing months or years after radiation treatment are known as late
radiation tissue injury (LRTI) and are estimated to effect 5%-15% of all long-term survivors
who have received radiation.

Hyperbaric oxygen therapy (HBOT) is a well established treatment of LRTI. Most of the studies
evaluating effect of HBOT on LRTI are focused on survival, resolution of tissue damage and
improvement in LENT-SOMA scale. Very few studies have addressed effect of HBOT on pain in
LTRI. Krahn and colleagues were the first to report the analgesic effect of HBOT in 3 cases
of refractory pain in oncological patients with radiation soft tissue injury. Other studies
showed significant improvement in pain intensity in patients with breast cancer and pelvic
malignancies treated with HBOT for LTRI. In patients that had developed radiation- induced
brachial plexopathy, HBOT elicited an increase in warm pain thresholds and a reduction in
lymphoedema. A prospective case study of 16 patients with gynecological cancer found no
changes with respect to pain and depression outcomes. A trial in patients with radiation
induced proctopathy showed that 75% of patients with rectal pain had some improvement,
although none experienced a complete resolution of pain symptoms.

There are several mechanisms by which HBOT may elicit analgesic effects. There is a growing
body of evidence that HBOT’s analgesic effect related to nitric oxide metabolism and
endogenous opioid secretion. Furthermore, the inhibition of tumor necrosis factor alph
(TNF-α), the production of substance P, and the modulation of serotonergic pathways have all
demonstrated a modification in the pain response following HBOT. In animal studies HBOT
decreased allodynia and hyperalgesia in different models of neuropathic and inflammatory
pain. The long lasting antinociceptive effect of HBOT was found to be dose-dependent in
non-injured tissues.

In human studies, HBOT decreased pain and edema and improved function in patients suffering
from the complex regional pain syndrome, and improved pain scores and range of motion in
patients with idiopathic femoral head necrosis. Women suffering from interstitial cystitis
demonstrated a reduction in pelvic pain following weeks and months of HBOT treatment. In
patients suffering from idiopathic trigeminal neuralgia HBOT produced a rapid reduction in
symptoms and these effects were lasting for 6 months following treatment. HBOT was also found
to be an effective treatment for cluster headaches and migraines and alleviated muscle and
bone pains in patients with myofascial syndrome, fibromyalgia, and biphosphonate-related
osteonecrosis of the jaw.

Based on the evidence presented above and HBOT’s known analgesic effect in many conditions,
the investigators designed this study with the objective to evaluate if HBOT reduces pain,
improves depression and impacts on patients quality of life in patients suffering from late
radiation tissue injury.

Study Design: Prospective observational study (n=300). Patients that have had radiation
therapy for malignancy, developed late radiation injury and suffer from chronic pain.

Clinical Trial – HBOT in Fibromyalgia

Fibromyalgia (FM) is a chronic pain condition affecting several millions of Canadians.
Although the etiology and pathophysiology are poorly understood, there is a well-recognized
association between muscular pain in fibromyalgia and muscular hypoperfusion, hypoxia,
abnormal muscle metabolism and oxidative stress. Currently there is no cure for FM.
Pharmacological and non-pharmacological strategies are directed to control symptoms such as
pain, fatigue, non-restorative sleep and depression.

Hyperbaric oxygen therapy (HBOT) is an intermittent inhalation of 100% oxygen in a hyperbaric
chamber at a pressure higher than 1 absolute atmosphere. Physiological effect of HBOT is
based on a dramatic increase in the amount of dissolved oxygen carried by the blood which
enables oxygenation of ischemic areas with compromised circulation. It also activates
oxidant-antioxidant system, stimulates angio- and neurogenesis, modulates inflammatory
response, induces brain neuroplasticity and possesses analgesic effect.

While some interventions offer benefit for some patients, additional treatment alternatives
are needed for patients with FM in whom currently available options are either ineffective or
poorly tolerated. Given its physiological effect, HBOT could be considered as a potential
therapy for treatment of underlying muscular hypoxia, optimizing oxidant- antioxidant system
and controlling FM symptoms. The results from this study could therefore provide new
information supporting the basic science underling the pathophysiology of this disease and
stimulate novel therapies for patients suffering with FM.